Global X China MedTech ETF

2841 HKD

Invest in 2841

Important Information

Investors should not base investment decisions on this website alone. Please refer to the Prospectus for details including product features and the risk factors. Investment involves risks. Past performance is not indicative of future performance. There is no guarantee of the repayment of the principal. Investors should note:

  • Global X China MedTech ETF’s (the “Fund’s”) objective is to provide investment results that, before fees and expenses, closely correspond to the performance of the Solactive China MedTech Index (the “Index”).
  • The Index is a new index. The Index has minimal operating history by which investors can evaluate its previous performance. There can be no assurance as to the performance of the Index. The Fund may be riskier than other exchange traded funds tracking more established indices with longer operating history.
  • The Fund may invest in small and/or mid-capitalisation companies. The stock of small-capitalisation and mid-capitalisation companies may have lower liquidity and their prices are more volatile to adverse economic developments than those of larger capitalisation companies in general.
  • The Fund’s investments are concentrated in companies in the medical technology industry. The value of the Fund may be more volatile than that of a fund having a more diverse portfolio of investments and may be more susceptible to adverse economic, political, policy, liquidity, tax, legal or regulatory event affecting the relevant industry.
  • Many of the companies with a high business exposure to a medical technology theme have a relatively short operating history. Rapid changes could render obsolete the products and services offered by these companies and cause severe or complete declines in the prices of the securities of those companies. Additionally, companies with medical technology themes may face dramatic and often unpredictable changes in growth rates and competition for the services of qualified personnel. They may potentially subject to (i) substantial government intervention in the technology industry (including restrictions on investment in internet and technology companies), (ii) complex laws and regulations including privacy, data protection, content regulation, intellectual property, competition, protection of minors, consumer protection and taxation, (iii) heavy and significant capital investment on research and development, (iv) risks of medical failure (including injury or death of patients), negligence or product liability claims, recall or withdrawal of products. These risks may result in adverse impact of the operating results of the companies.
  • The Mainland China is an emerging market. The Fund invests in Mainland Chinese companies which may involve increased risks and special considerations not typically associated with investment in more developed markets, such as liquidity risk, currency risks or control, political and economic uncertainties, legal and taxation risks, settlement risks, custody risk and the likelihood of a high degree of volatility. Securities exchanges in the Mainland Chinese markets typically have the right to suspend or limit trading in any security traded on the relevant exchange. The government or the regulators may also implement policies that may affect the financial markets. All these may have a negative impact on the Fund.
  • Listed companies on the ChiNext market and/or STAR Board are subject to higher fluctuation on stock prices and liquidity risk, over-valuation risk, less stringent regulation risk, delisting risk and concentration risk.
  • The Fund’s synthetic replication strategy will involve investing up to 50% of its net asset value in financial derivative instruments (“FDIs”), mainly funded total return swap transaction(s) through one or more counterparty(ies). Risks associated with FDIs include counterparty/credit risk, liquidity risk, valuation risk, volatility risk and over-the-counter transaction risk. FDIs are susceptible to price fluctuations and higher volatility, and may have large bid and offer spreads and no active secondary markets. The leverage element/component of an FDI can result in a loss significantly greater than the amount invested in the FDI by the Fund.
  • As part of the securities lending transactions, there is a risk of shortfall of collateral value due to inaccurate pricing of the securities lent or change of value of securities lent. This may cause significant losses to the Fund. The borrower may fail to return the securities in a timely manner or at all. The Fund may suffer from a loss or delay when recovering the securities lent out. This may restrict the Fund’s ability in meeting delivery or payment obligations from redemption requests.
  • The trading price of the Shares on the Stock Exchange of Hong Kong is driven by market factors such as the demand and supply of the Shares. Therefore, the Shares may trade at a substantial premium or discount to the Fund’s Net Asset Value.
  • Payments of distributions out of capital or effectively out of capital amounts to a return or withdrawal of part of an investor’s original investment or from any capital gains attributable to that original investment. Any such distributions may result in an immediate reduction in the Net Asset Value per Share of the Fund and will reduce the capital available for future investment.

Why Invest ?

Targeted Access to Chinese medical device stocks

Global X China MedTech ETF offers investors an opportunity to gain exposure to Chinese companies involved in the manufacturing and distribution of medical devices. The fund's focus is on capturing growth opportunities in both the domestic market and the export manufacturing sector.

High Growth Potential

The Chinese medical device industry, comprising both equipment and consumables, is anticipated to exhibit substantial growth potential in the global market.

Diversified Portfolio

The portfolio is well-diversified, encompassing high-value imaging, patient monitoring systems, high-value consumables, and products related to diagnostics.

Fund InformationAs of 1 Dec 2023

Fund Inception Date 03 Aug 2023
SEHK Listing Date 04 Aug 2023
Fiscal Year Ending 31 Mar
Ongoing Charges Over A Year ^ 0.68%
Distribution Frequency Annually (usually in May of each year) at the Manager’s discretion. *
^ The Fund adopts a single management fee structure, whereby a single flat fee will be paid out of the assets of the Fund to cover all of the costs, fees and expenses of the Fund. Click to learn more. * Dividend is not guaranteed, distributions may be made out of capital or income at the Manager’s discretion. Please refer to the IMPORTANT INFORMATION section above and the Fund’s prospectus for further details.

Index Information 1 As of 1 Dec 2023

Underlying Index Solactive China MedTech Index 2
Index Type Net Total Return
Base Currency RMB
Closing Level 1,115.93
Change -3.69
Change % -0.33%

ETF Objective

The investment objective of the Sub-Fund is to provide investment results that, before fees and expenses, closely correspond to the performance of the Solactive China MedTech Index (the “Index”).

Trading InformationAs of 1 Dec 2023

Exchange Hong Kong Stock Exchange
Stock Code 2841
ISIN HK0000945649
Board Lot Size 50 Units
Trading Currency HKD
Total Net Asset Value $54,228,638.41
Outstanding Units 1,100,000

Near Real Time Estimated NAV per Unit4

-- $ --
-- $ --

* Market prices are provided on a 15-minute delayed basis by ICE Data Services. (See terms and conditions)

Daily NAV per Unit5As of 1 Dec 2023

NAV Change % Change
Official NAV per Unit in RMB $45.08 $-0.15 -0.34%
NAV per Unit in HKD 3 $49.30 $-0.17 -0.34%


Cumulative Return Fund NAV (%) Benchmark (%)
1 Mth - -
3 Mths - -
6 Mths - -
1 Yr - -
YTD - -
Since Inception - -
Calendar Year Return Fund NAV (%) Benchmark (%)
^ Since listing date to the end of the calendar year.
Source: Mirae Asset Global Investments (Hong Kong) Limited.
• Past performance information is not indicative of future performance. Investors may not get back the full amount invested.
• The computation basis of the performance is based on the calendar year end, NAV-to-NAV, with dividend reinvested.
• These figures show by how much the Fund increased or decreased in value during the calendar year shown.
• Performance data has been calculated in RMB including ongoing charges and excluding trading costs on SEHK you might have to pay.
• Where no past performance is shown there was insufficient data available in that year to provide performance.
• The Index of the Fund is Solactive China MedTech Index.
• Fund launch date: 3 Aug 2023

Holdings Overview As of 1 Dec 2023

Total Net Asset Value (in HKD) Total Net Asset Value (in USD) Number of Securities Securities (%) Cash and Cash Equivalent (%)
54,228,638.41 6,939,067.45 30 99.11 0.89

Daily HoldingsAs of 1 Dec 2023

Name of Securities Exchange Ticker Exchange Market Price (in RMB) Number of Shares Held Market Value (in RMB) Net Assets (%)
SHENZHEN MINDRAY BIO-MEDIC 300760 C2 Shenzhen 290.10 16,444 4,770,404.40 9.62
AIER EYE HOSPITAL GROUP CO 300015 C2 Shenzhen 17.00 261,012 4,437,204.00 8.95
JD HEALTH INTERNATIONAL INC 6618 HK Hong Kong 33.15 99,291 3,291,237.91 6.64
IMEIK TECHNOLOGY DEVELOPME 300896 C2 Shenzhen 298.00 10,997 3,277,106.00 6.61
SHENZHEN NEW INDUSTRIES BI 300832 C2 Shenzhen 72.61 39,588 2,874,484.68 5.80
ALIBABA HEALTH INFORMATION T 241 HK Hong Kong 4.00 673,483 2,691,221.58 5.43
GENSCRIPT BIOTECH CORP 1548 HK Hong Kong 19.66 125,419 2,465,716.69 4.97
JIANGSU YUYUE MEDICAL EQU 002223 C2 Shenzhen 33.79 51,086 1,726,195.94 3.48
SHANDONG WEIGAO GP MEDICAL 1066 HK Hong Kong 6.60 241,388 1,593,654.80 3.21
AUTOBIO DIAGNOSTICS CO LTD 603658 C1 Shanghai 53.48 29,778 1,592,527.44 3.21
LEPU MEDICAL TECHNOLOGY 300003 C2 Shenzhen 17.03 91,014 1,549,968.42 3.13
WINNING HEALTH TECHNOLOGY 300253 C2 Shenzhen 7.79 171,880 1,338,945.20 2.70
SONOSCAPE MEDICAL CORP 300633 C2 Shenzhen 51.59 25,554 1,318,330.86 2.66
MEINIAN ONEHEALTH HEALTHCA 002044 C2 Shenzhen 6.18 207,699 1,283,579.82 2.59
APT MEDICAL INC 688617 C1 Shanghai 377.72 3,226 1,218,524.72 2.46
WINNER MEDICAL CO LTD 300888 C2 Shenzhen 38.71 31,362 1,214,023.02 2.45
IRAY TECHNOLOGY CO LTD 688301 C1 Shanghai 214.39 5,633 1,207,658.87 2.44
BGI GENOMICS CO LTD 300676 C2 Shenzhen 51.68 22,504 1,163,006.72 2.35
MICROPORT SCIENTIFIC CORP 853 HK Hong Kong 11.47 96,691 1,108,727.88 2.24
OVCTEK CHINA INC 300595 C2 Shenzhen 24.44 45,148 1,103,417.12 2.23
JAFRON BIOMEDICAL CO LTD 300529 C2 Shenzhen 24.16 45,421 1,097,371.36 2.21
SINOCARE INC 300298 C2 Shenzhen 29.82 35,325 1,053,391.50 2.12
ANDON HEALTH CO LTD 002432 C2 Shenzhen 37.23 26,455 984,919.65 1.99
PING AN HEALTHCARE AND TECHN 1833 HK Hong Kong 15.76 60,143 948,120.92 1.91
DOUBLE MEDICAL TECHNOLOGY 002901 C2 Shenzhen 40.62 22,067 896,361.54 1.81
INTCO MEDICAL TECHNOLOGY C 300677 C2 Shenzhen 20.60 35,847 738,448.20 1.49
BEIJING STRONG BIOTECHNOLO 300406 C2 Shenzhen 20.31 35,267 716,272.77 1.44
ANGELALIGN TECHNOLOGY INC 6699 HK Hong Kong 54.09 9,926 536,871.56 1.08
AMOY DIAGNOSTICS CO LTD 300685 C2 Shenzhen 22.36 21,603 483,043.08 0.97
JINXIN FERTILITY GROUP LTD 1951 HK Hong Kong 3.37 138,808 467,093.36 0.94
Holdings are subject to change. Cash, where shown, includes other assets and liabilities, such as payables and receivables.

Tracking Difference / Error

Tracking Difference / Tracking Error

Tracking Difference
Tracking difference is the return difference between the Fund and the Underlying Index over a certain period of time.
Tracking Error
Tracking error measures how consistently the Fund follows the Underlying Index. It is the volatility (measured by standard deviation) of that return difference.

Tracking Difference (TD)

Fund Listing Date:4 Aug 2023

Estimated Annual TD: -2.00%

TD (Since Listing): N/A%

Tracking Error (TE)

Fund Listing Date:4 Aug 2023

Rolling 1 Year TE^ :N/A%

^ Annualized based on the number of dealing days in the past year when daily TD is calculated.

Graph for Tracking Difference

ETFs performance is calculated on an NAV to NAV basis and assumes reinvestment of distribution.

Hover over the chart points for details

Market Makers 6

Mirae Asset Securities Co., Limited

Flow Traders Hong Kong Limited

Participating Dealers 7

Haitong International Securities Company Limited

Mirae Asset Securities (HK) Limited

Citigroup Global Markets Asia Limited

Valuable Capital Limited

Back to Top

You’re now leaving Global X Hong Kong website

Clicking "Confirm" below will take you to an independent site. Information and services provided on this independent site are not reviewed by, guaranteed by, or Global X Hong Kong. This independent site's terms and conditions, privacy and security policies, or other legal information may be different from those of Global X Hong Kong’s site. Global X Hong Kong is not liable for any direct or indirect technical or system issues, consequences, or damages arising from your use of this independent website.


This website is intended for Hong Kong investors only. Your use of this website means you agree to our Terms of use. This website is strictly for informational purposes only and does not constitute a representation that any investment strategy is suitable or appropriate for an investor’s individual circumstances. In 2018, Global X was acquired by Mirae Asset Global Investments and Mirae Asset Global Investments Co., Ltd. is the parent company of Mirae Asset Global Investments (Hong Kong) Limited.

The information contained in this website is for information purposes only and does not, constitute any recommendations, offer or solicitation to buy, sell or subscribe to any securities or financial instruments in any jurisdiction. Investment involves risk. It cannot be guaranteed that the performance of the Product will generate a return and there may be circumstances where no return is generated or the amount invested is lost. Past performance is not indicative of future performance.

Before making any investment decision to invest in the Product, investors should read the Product’s prospectus for details and the risk factors. Investors should ensure they fully understand the risks associated with the Product and should also consider their own investment objective and risk tolerance level. Investors are advised to seek independent professional advice before making any investments.

Certain information contained in this website is compiled from third party sources. Whilst Mirae Asset Global Investments (Hong Kong) Limited (“Mirae Asset HK”), the Manager of the Product, has, to the best of its endeavor, ensured that such, information is accurate, complete and up-to-date, and has taken care in accurately reproducing the information. Mirae Asset HK accepts no liability for, any loss or damage of any kind resulting out of the unauthorized use of this website.

The Products are not sponsored, endorsed, issued, sold or promoted by their index providers. For details of an index provider including any disclaimer, please refer to the relevant Product’s offering documents.

The contents of this website is prepared and maintained by Mirae Asset Global Investments (Hong Kong) Limited and has not been reviewed by the Securities and Futures Commission of Hong Kong.